Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 300 of 3499 entries
View as:

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Phase: N/A Priority: Normal
NCT ID: NCT03707574 Org: User:
Start: 07/16/19 End: 03/07/26 Due: 03/07/27

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00069160 Org: User:
Start: 09/30/03 End: 12/31/09 Due: 12/31/10

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00003765 Org: User:
Start: 05/31/99 End: - Due: -

Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT00103259 Org: User:
Start: 07/31/05 End: 11/30/11 Due: 11/30/12

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Phase: N/A Priority: Normal
NCT ID: NCT01462695 Org: User:
Start: 01/31/12 End: 03/31/14 Due: 03/31/15

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00066768 Org: User:
Start: 07/31/03 End: - Due: -

Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00416793 Org: User:
Start: 12/31/06 End: 12/31/09 Due: 12/31/10

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01576172 Org: User:
Start: 03/30/12 End: 04/23/20 Due: 04/23/21

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005817 Org: User:
Start: 03/31/00 End: - Due: -

A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00001502 Org: User:
Start: 04/30/96 End: 03/31/00 Due: 03/31/01

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00036751 Org: User:
Start: 04/30/02 End: - Due: -

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00027599 Org: User:
Start: 12/31/01 End: - Due: -

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02003222 Org: User:
Start: 05/19/14 End: 03/25/26 Due: 03/25/27

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00243035 Org: User:
Start: 08/31/05 End: - Due: -

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03030378 Org: User:
Start: 05/30/18 End: 12/01/25 Due: 12/01/26

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01074411 Org: User:
Start: 04/05/10 End: 01/27/18 Due: 01/27/19

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03953898 Org: User:
Start: 08/04/20 End: 02/20/26 Due: 02/20/27

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men

Phase: N/A Priority: Normal
NCT ID: NCT00287833 Org: User:
Start: 01/31/06 End: - Due: -

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00075751 Org: User:
Start: 01/31/04 End: - Due: -

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase: N/A Priority: Normal
NCT ID: NCT01519427 Org: User:
Start: 01/31/12 End: 05/31/13 Due: 05/31/14

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02504892 Org: User:
Start: 07/21/15 End: 04/17/18 Due: 04/17/19

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01757639 Org: User:
Start: 12/14/12 End: - Due: -

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00126542 Org: User:
Start: 04/30/05 End: 04/30/10 Due: 04/30/11

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00103194 Org: User:
Start: 09/30/05 End: 06/30/13 Due: 06/30/14

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03925428 Org: User:
Start: 09/18/20 End: 09/18/20 Due: 09/18/21